Sector: MedicalAlkermes, Inc. (NASDAQ: ALKS)
Headlines
- Alkermes Initiates Phase 2 Clinical Study of ALKS 33 for the Treatment of Alcohol Dependence
Nov 17, 2009 08:30 AM | ALKS
- Movers and downers in the market for Monday the 16th
Nov 16, 2009 03:00 PM | ADY, ALKS, APOL, BMY, IBKC, INTC
- BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
Nov 16, 2009 11:56 AM | ALKS, CRL, CRXX, CYTX, HGSI, HHS
- Alkermes Announces Positive Results from Phase 3 Clinical Study of Naltrexone for Extended-Release Injectable Suspension for the Treatment of Opioid Dependence
Nov 16, 2009 08:14 AM | ALKS
- Alkermes' Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference
Nov 10, 2009 04:00 PM | ALKS
- Big Pharma And Biotech - Industry Outlook
Nov 09, 2009 06:03 PM | ABT, ACL, ACOR, ALKS, AZN, BBI
- Alkermes Reports Second Quarter Fiscal 2010 Financial Results
Nov 05, 2009 04:00 PM | ALKS, JNJ
- Alkermes' Corporate Presentation to be Webcast at the Credit Suisse Healthcare Conference
Nov 04, 2009 04:00 PM | ALKS
- Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2010
Oct 29, 2009 04:00 PM | ALKS
- Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation
Oct 27, 2009 08:30 AM | ALKS, RX
- RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on ALV, CLS, VIT, TKC, CRK and ALKS
Oct 13, 2009 08:12 AM | ALKS, ALV, CLS, CRK, TKC, VIT
- Alkermes Reports First Quarter Fiscal 2010 Financial Results
Aug 06, 2009 04:04 PM | ALKS
- Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2010
Jul 30, 2009 04:05 PM | ALKS
- Alkermes’ Corporate Presentation to be Webcast at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
Jul 29, 2009 04:04 PM | ALKS
- BenchmarkJournal.Com Free Analyst Review for ITUB, APWR, CHRS, FMBI, ALKS and HANS
Jul 22, 2009 10:24 AM | ALKS, APWR, CHRS, FMBI, HANS
- Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
Jul 20, 2009 04:15 PM | ALKS, AMLN, LLY
- Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus® in Head-to-Head DURATION-3 Study
Jul 20, 2009 04:07 PM | ALKS
- New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
Jul 07, 2009 04:05 PM | ALKS, AMLN, LLY
- Alkermes' Corporate Presentation to be Webcast at the Jefferies & Company 3rd Annual Healthcare Conference
Jun 10, 2009 04:03 PM | ALKS
- Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control with Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
Jun 07, 2009 09:16 AM | ALKS
- Form 4 ALKERMES INC For: Nov 18 Filed by: Ehrich Elliot (10K)
Nov 20, 2009 02:12 PM
- Form 4 ALKERMES INC For: Nov 18 Filed by: BIBERSTEIN KATHRYN L (10K)
Nov 20, 2009 02:12 PM
- Form 4 ALKERMES INC For: Nov 18 Filed by: LANDINE MICHAEL J (10K)
Nov 20, 2009 02:11 PM
- Form 4 ALKERMES INC For: Nov 18 Filed by: FRATES JAMES M (10K)
Nov 20, 2009 02:11 PM
- Form 4 ALKERMES INC For: Nov 18 Filed by: POPS RICHARD F (10K)
Nov 20, 2009 02:10 PM
- Form 4 ALKERMES INC For: Nov 18 Filed by: Pugh Gordon G (10K)
Nov 20, 2009 02:09 PM
- Form 4 ALKERMES INC For: Nov 05 Filed by: BIBERSTEIN KATHRYN L (10K)
Nov 06, 2009 02:06 PM
- Form 4 ALKERMES INC For: Oct 06 Filed by: WALL MICHAEL A (10K)
Oct 08, 2009 05:46 PM
- Form 4 ALKERMES INC For: Oct 06 Filed by: SKALETSKY MARK B (10K)
Oct 08, 2009 05:43 PM
- Form 4 ALKERMES INC For: Oct 06 Filed by: RICH ALEXANDER (10K)
Oct 08, 2009 05:40 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
ALKS
|
Compare to S&P
|
| YTD |
-25.73 %
|
-38.65 %
|
| 4 Weeks |
-12.01 %
|
-12.48 %
|
| 12 Weeks |
-24.01 %
|
-28.69 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 18.18 %
|
|
EPS Growth in Last Year: -550.00 %
|
|
Sales Growth in Last Quarter: 1.39 %
|
|
Sales Growth in Last Quarter: 1.79 %
|
|
